Prime Capital Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Prime Capital Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,515	Closed	-$859K	–	1133
2025 Q1	$859K	Buy	6,515 +1,084	+20%	+$135K	0.01%	539
2024 Q4	$454K	Sell	5,431 -1,989	-27%	-$163K	0.01%	592
2024 Q3	$543K	Sell	7,420 -391	-5%	-$29.4K	0.01%	568
2024 Q2	$535K	Buy	7,811 +55	+0.7%	+$3.81K	0.01%	558
2024 Q1	$537K	Sell	7,756 -1,412	-15%	-$97K	0.01%	605
2023 Q4	$657K	Buy	9,168 +2,743	+43%	+$158K	0.01%	510
2023 Q3	$335K	Sell	6,425 -16,300	-72%	-$950K	0.01%	556
2023 Q2	$1.44M	Buy	22,725 +7,500	+49%	+$467K	0.03%	300
2023 Q1	$824K	Buy	+15,225	New	+$736K	0.03%	271

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prime Capital Investment Advisors's ITCI Position: Q2 2025 in Review

Prime Capital Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 6,515 shares — an estimated $859K sold.

Prime Capital Investment Advisors first reported a position in ITCI in Q1 2023 and held it in 9 quarters. The position peaked at $1.44M in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Prime Capital Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Prime Capital Investment Advisors sold 6,515 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $859K.
Prime Capital Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 9 quarters.
Prime Capital Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $1.44M in Q2 2023.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.